MicroRNA Expression Signature in Mild Cognitive Impairment Due to Alzheimer's Disease

Area of Science:

• Neuroscience
• Molecular Biology
• Genetics

Background:

• Mild cognitive impairment (MCI) represents a transitional stage between normal aging and dementia, including Alzheimer's disease (AD).
• Early identification of MCI patients who will progress to AD (MCI-AD) is critical for developing timely therapeutic interventions.
• MicroRNAs (miRNAs) are increasingly implicated in the pathogenesis of AD, with specific miRNA-disease associations under investigation.

Purpose of the Study:

• To analyze the microRNA transcriptome composition in biological samples from MCI-AD subjects.
• To identify specific miRNAs dysregulated in MCI-AD patients compared to controls.
• To explore the potential of these miRNAs as biomarkers for MCI-AD progression.

Main Methods:

• Analysis of microRNA transcriptome in blood, serum, and cerebrospinal fluid (CSF) from MCI-AD subjects using an enriched small RNA library.
• Real-time quantitative PCR (qPCR) to profile miRNA expression in MCI-AD patients, AD patients, and normal controls.
• Target prediction analysis to identify messenger RNAs (mRNAs) regulated by dysregulated miRNAs.

Main Results:

• Four miRNAs (hsa-mir-5588-5p, hsa-mir-3658, hsa-mir-567, and hsa-mir-3908) were found to be dysregulated in MCI-AD patients.
• Hsa-mir-567 exhibited significant differential expression across CSF, blood, and serum samples from MCI-AD patients, with the highest fold change.
• Target prediction indicated that hsa-mir-567 targets genes are functionally active in neuronal cells.

Conclusions:

• The identified miRNA profiles in MCI-AD patients offer insights into AD-related cognitive decline.
• Dysregulated miRNAs, particularly hsa-mir-567, show potential as diagnostic or prognostic biomarkers for MCI-AD progression to AD.
• Further research into these miRNA signatures could facilitate the development of novel therapeutic strategies for AD.